Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza virus vaccine live intranasal (quadrivalent) - MedImmune

Drug Profile

Influenza virus vaccine live intranasal (quadrivalent) - MedImmune

Alternative Names: Fluenz Tetra; FluMist Quadrivalent; Influenza vaccine live-intranasal - MedImmune; MEDI-3250; MEDI-8662; Q-LAIV Flu Vac; Q-LAIV Flu Vaccination; Q/LAIV; Quadrivalent live attenuated influenza vaccine - MedImmune; Quadrivalent live attenuated seasonal influenza vaccine - MedImmune; VN-0107

Latest Information Update: 04 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca; Japan Vaccine; MedImmune
  • Class Influenza virus vaccines live
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 01 Apr 2018 Registered for Influenza virus infections (Prevention, In children, In adolescents, In adults) in Hong Kong (Intranasal)
  • 21 Feb 2018 The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) votes in favour of a renewed recommendation for the use of influenza virus intranasal vaccine for 2018-2019 season in USA
  • 21 Feb 2018 Immunogenicity data from a phase IV trial in Influenza virus infections released by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top